ParvOryx: Phase I/IIa started

Oryx began an open-label, dose-escalation, German Phase I/IIa trial to evaluate 3 dose levels of ParvOryx in 7 patients with inoperable tumors having >=1 hepatic metastasis. Patients will receive IV P...